Igen Biolab Group
  • Home
  • About us
  • Pipeline
  • Tecnology
  • Press
    • News
    • Press Releases
    • Events
    • Publications
  • Contact
  • English
    • Español
Select Page
Nasopharyngeal Microbiota as an early severity biomarker in COVID-19 hospitalised patients

Nasopharyngeal Microbiota as an early severity biomarker in COVID-19 hospitalised patients

by Igen BioLab Group | Mar 15, 2022 | News, Publications

This study aimed to analyse the diversity and taxonomic composition of the nasopharyngeal microbiota, to determine its association with COVID-19 clinical outcome. To study the microbiota, we utilized 16S rRNA sequencing of 177 samples that came from a retrospective...
The role of gut microbiome in cancer genesis and cancer prevention

The role of gut microbiome in cancer genesis and cancer prevention

by Igen BioLab Group | Mar 11, 2022 | News, Publications

Cancer is the second leading cause of fatalities at the global level, and the involvement of microbes in several diseases, including cancer is well known. The gut microbiome is known to have an essential role in the regulation of the host’s health and...
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

by Igen BioLab Group | Mar 3, 2022 | News, Publications

Previous studies have suggested that the gut microbiome influences the response to checkpoint inhibitors (CPIs) in patients with cancer. CBM588 is a bifidogenic live bacterial product that we postulated could augment CPI response through modulation of the gut...
Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1

Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1

by Igen BioLab Group | Mar 3, 2022 | News, Publications

Ample evidence indicates that the gut microbiome is a tumor-extrinsic factor associated with antitumor response to anti-programmed cell death protein-1 (PD-1) therapy, but inconsistencies exist between published microbial signatures associated with clinical outcomes....
Current status of intratumour microbiome in cancer and engineered exogenous microbiota as a promising therapeutic strategy

Current status of intratumour microbiome in cancer and engineered exogenous microbiota as a promising therapeutic strategy

by Igen BioLab Group | Feb 10, 2022 | News, Publications

Research on the relationship between microbiome and cancer has made significant progress in the past few decades. It is now known that the gut microbiome has multiple effects on tumour biology. However, the relationship between intratumoral bacteria and cancers...
The gut microbiota can be a potential regulator and treatment target of bone metastasis

The gut microbiota can be a potential regulator and treatment target of bone metastasis

by Igen BioLab Group | Feb 7, 2022 | News, Publications

The gut microbiota, an often forgotten organ, have a tremendous impact on human health. It has long been known that the gut microbiota are implicated in cancer development, and more recently, the gut microbiota have been shown to influence cancer metastasis to distant...
A natural polyphenol exerts antitumor activity and circumvents anti-PD-1 resistance through effects on the gut microbiota

A natural polyphenol exerts antitumor activity and circumvents anti-PD-1 resistance through effects on the gut microbiota

by Igen BioLab Group | Feb 4, 2022 | News, Publications

Several approaches to manipulate the gut microbiome for improving the activity of cancer immune checkpoint inhibitors (ICI) are currently under evaluation. Here, we show that oral supplementation with the polyphenol-rich berry camu-camu (CC, Myrciaria dubia) in mice...
Scientists discover link between gut microbiota and chronic inflammatory diseases like arthritis

Scientists discover link between gut microbiota and chronic inflammatory diseases like arthritis

by Igen BioLab Group | Jan 27, 2022 | News

An international research team has established a link between gut microbiota and chronic inflammatory diseases such as arthritis. The team led by Éric Boilard of Université Laval has discovered that a protein naturally present in the gut acts on the microbiota and...
International Conference on Microbiome Research

International Conference on Microbiome Research

by Igen BioLab Group | Jan 26, 2022 | Events, News

The International Research Conference is a federated organization dedicated to bringing together a significant number of diverse scholarly events for presentation within the conference program. Events will run over a span of time during the conference depending on the...
Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis

Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis

by Igen BioLab Group | Jan 14, 2022 | Publications

The microbiota comprises the microorganisms that live in close contact with the host, with mutual benefit for both counterparts. The contribution of the gut microbiota to the emergence of castration-resistant prostate cancer (CRPC) has not yet been addressed. We found...
« Older Entries
Next Entries »

Recent Posts

  • Microbial link between Western-style diet and incidence of colorectal cancer uncovered
  • Intratumor microbiome in cancer progression: current developments, challenges and future trends
  • Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy
  • Colorectal microbiota after removal of colorectal cancer
  • Targeting the microbiome in patients with melanoma – ready for prime time?
  • LEGAL NOTICE
  • PRIVACY AND DATA PROTECTION
  • Cookie policy
  • Facebook
  • Twitter
  • Instagram
  • RSS
Design by loComunicas

This website uses its own and third-party cookies in order to analyze the traffic generated for statistical purposes.

You can accept all cookies by clicking "Accept", reject all of them by clicking "Deny" or configure them by clicking "Settings".

For more information on how this site uses cookies and related technologies, you can read our Policy on Cookies

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly necessary cookies

Strictly necessary cookies must always be activated so that we can save your cookie settings preferences.

If you deactivate this cookie, we will not be able to save your preferences. This means that every time you visit this website you will have to activate or deactivate cookies again.

Third party cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, or the most popular pages.

Leaving this cookie active allows us to improve our website.

Please activate the strictly necessary cookies first so that we can save your preferences!

Cookies policy

More information about our cookie policy